In April 2017, Moderna published human data for
its mRNA vaccine technology in Molecular Therapy, which showed that its first prophylactic vaccine candidate, mRNA - 1440 — an mRNA prophylactic vaccine against avian H10N8 influenza — induced high levels of immunogenicity and was safe and well tolerated.